Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 0 · 0%

Intervention not reported

All‐cause mortality (ticlopidine vs placebo) · patients with type 2 diabetes mellitus

The intervention showed no clear difference in all‐cause mortality (ticlopidine vs placebo) (moderate certainty).

1 finding from 1 review

Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes… 2012 · Cochrane Headline outcomes only
RR 1.29 [0.71, 2.32]
1 study · 335 participants
Moderate

Intervention not reported

Vascular mortality (ticlopidine vs placebo) · patients with type 2 diabetes mellitus

The intervention showed no clear difference in vascular mortality (ticlopidine vs placebo) (moderate certainty).

1 finding from 1 review

Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes… 2012 · Cochrane Headline outcomes only
RR 0.94 [0.47, 1.88]
1 study · 335 participants
Moderate

Intervention not reported

Myocardial infarction (fatal and non‐fatal) (ticlopidine vs placebo) · patients with type 2 diabetes mellitus

The intervention showed no clear difference in myocardial infarction (fatal and non‐fatal) (ticlopidine vs placebo) (moderate certainty).

1 finding from 1 review

Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes… 2012 · Cochrane Headline outcomes only
RR 0.78 [0.39, 1.57]
1 study · 335 participants
Moderate

Intervention not reported

Stroke (fatal and non‐fatal) (a. ticlopidine vs aspirin) (b. clopidogrel vs aspirin & dipyramidole) · patients with type 2 diabetes mellitus

The intervention probably leads to lower stroke (fatal and non‐fatal) (a. ticlopidine vs aspirin) (b.… (moderate certainty).

1 finding from 1 review

Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes… 2012 · Cochrane Headline outcomes only
RR 0.56 [0.37, 0.94]
1 study · 597 participants
Moderate

Intervention not reported

Health‐related quality of life · patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes… 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse effects · patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes… 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Costs · patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes… 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found